The Federal Circuit affirmed the decision of the District of Delaware that claims of Otsuka Pharmaceutical Co. Ltd.'s patents that discloses highly pure tolvaptan and improved methods for synthesizing tolvaptan weren’t infringed by Lupin Ltd. and Lupin Pharmaceuticals Inc.’s manufacturing process incorporated in an abbreviated new drug application, and that certain claims of one of the patents were invalid as obvious over prior art.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.